Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment

K Oinuma, Y Harada, Y Nawata, K Takabayashi, I Abe, K Kamikawa, H Moriya

Abstract

Objectives—To investigate the actual time of onset of osteonecrosis (ON) after high dose corticosteroid treatment in systemic lupus erythematosus (SLE).

Methods—72 patients with active SLE, who received high dose corticosteroid for the first time, for the development of ON at hips and knees were monitored by magnetic resonance imaging for at least 12 months.

Results—ON lesions were detected in 32/72 patients (44%) between one and five months (3.1 months on average) after starting high dose corticosteroid treatment. No osteonecrotic lesion was newly detected from the sixth month of treatment until the end of the follow up period. Conclusion—The findings suggested that the actual time of onset of ON in SLE is within the first month of high dose corticosteroid treatment.

It is well known that osteonecrosis (ON) frequently develops in patients with systemic lupus erythematosus (SLE) with a prevalence ranging from 10% to 52%.1–4 and that the development of ON in SLE is closely related to the high doses of corticosteroids received. Previous clinical studies have provided conflicting results about the possible association of corticosteroid treatment with the development of ON. The total treatment period,1 the highest daily dose,2 a continuous high dose,4 and the cumulative dose of corticosteroid5 have been reported as risk factors of ON in SLE. These conflicting results seem to be mainly due to the difficulties in detecting early ON, which occurs silently and cannot be based on conventional radiographic images. Magnetic resonance imaging (MRI) has proved to be more sensitive than conventional methods, such as radiography, computed tomography, and skeletal scintigraphy, for the detection of very early, asymptomatic ON.6

We investigated the actual time of onset of ON in SLE after starting high dose corticosteroid treatment using serial MR images of both hips and both knees obtained every three months, during one year.

Results

CHARACTERISTICS OF PATIENTS WITH OR WITHOUT OSTEONECROTIC LESIONS

Table 1 shows the clinical profiles of patients in the ON group and non-ON group. The ON group comprised 32 patients (29 women, three men) with a mean age of 34.1 (range 16–66). Abnormal MRI findings were found in the hip, knee, or both. The non-ON group comprised 40 patients (39 women, one man) with a mean age of 35.1 (range 13–63). The initial mean (SD) corticosteroid dose was 58.2 (10.1) mg/day in the ON group and 58.6 (16.6) mg/day in the non-ON group. Seventeen patients in the ON group and 18 in the...
Table 1 Baseline characteristics of the groups with and without osteonecrosis (ON)

<table>
<thead>
<tr>
<th></th>
<th>ON group</th>
<th>Non-ON group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>34.1 ± 9.9</td>
<td>35.1 ± 9.9</td>
</tr>
<tr>
<td>Range</td>
<td>16–66</td>
<td>13–63</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>10</td>
<td>24</td>
</tr>
<tr>
<td>Female</td>
<td>29</td>
<td>39</td>
</tr>
<tr>
<td>Initial corticosteroid dose† (mg/day equivalent prednisolone)</td>
<td>58.2 (10.1)</td>
<td>58.6 (16.6)</td>
</tr>
<tr>
<td>SLEDAI†</td>
<td>27.2 (12.3)</td>
<td>25.1 (9.8)</td>
</tr>
</tbody>
</table>

*SLEDAI = SLE Disease Activity Index; MPPT = methylprednisolone pulse treatment.
†Mean (SD).

Detection of Osteonecrotic Lesions by MRI

In the ON group, osteonecrotic lesions were detected by MRI performed at 3.1 months of treatment on average (range 1–5) after starting high dose corticosteroid treatment (fig 1). In 14 patients (Nos 19–32) of the ON group, the MR images obtained at 92.6 (22.0) days already showed osteonecrotic lesions. On the other hand, in 18 patients (Nos 1–18) of the ON group, osteonecrotic lesions were not detected by the MR images obtained at 39.6 (19.9) days, but they appeared soon after (100.2 (27) days). No osteonecrotic lesions were found to have developed after five months. These results indicate that osteonecrotic lesions develop after 39.6 days and before 100.2 days of treatment. All osteonecrotic lesions detected by MRI showed well demarcated, band-like zones of decreased signal intensity on T1 weighted, SE images (fig 2). All patients in the ON group were clinically asymptomatic.

Distribution of Osteonecrotic Joints

In the ON group 92 joints had osteonecrotic lesions—44 hips in 23 patients and 48 knees in 27 patients in the ON group (fig 1). Most patients (n=28) with ON had more than one joint affected—14 patients had four joints, four patients had three joints, and 10 patients had two joints. Bilaterality was common, being found in 91% of the hips and 77% of the knees.

Discussion

We believe this is the first study to investigate the actual time of onset of ON after high dose corticosteroid treatment in SLE using MRI. In this study, ON lesions, which were seen as well demarcated band-like zones, were detected by MRI at an average of 3.1 months after starting corticosteroid treatment. In a recent MRI study of patients who had received a renal transplant, ON lesions were detected at 1–4 months after starting high dose corticosteroid treatment." Although this study showed the presence of ON at the time of MRI, the actual time of onset of ON was not clarified.

In this paper we showed that ON lesions appeared on MRI early after starting corticosteroid treatment—namely, between 39.6 and 100.2 days of treatment. Our observations indicated that early development of ON in SLE...
was related to an event just after high dose corticosteroid treatment, and was not related to the total treatment period, the highest daily dose, a continuous high dose, or the cumulative dose of corticosteroid. Although corticosteroid is a well known cause of ON in SLE, clinical studies attempting to demonstrate an association of corticosteroid treatment with the development of ON in SLE have yielded conflicting results. This conflict seems to be mainly caused by the employment of conventional methods, such as x-ray examination and bone scintigraphy, in many of the previous studies. Many patients with early ON, which might have been detected by MRI, were probably missed by these conventional methods. MRI has proved to be the most useful method to detect early stage ON lesions that remain occult, clinically, radiologically, and scintigraphically.

Our study suggested that the actual onset of ON in SLE may be within the first month after starting high dose corticosteroid treatment because the first MR images in 14 patients were obtained significantly later than those of the 18 remaining patients in the ON group (92.6 (22.0) days vs 39.6 (19.9) days, p<0.0001).

We speculate that high dose corticosteroid treatment may enhance the development of ON as a result of microvascular ischaemia in patients with SLE who have vasculitis. It has been reported that corticosteroids decrease bone blood flow, thereby enhancing ischaemia owing to increased bone marrow pressure produced by intramedullary lipocytes hypertrophy. On the other hand, it was also reported that patients with SLE present haemostatic abnormalities, resulting from vascular endothelial damage, therefore, measurement of haemostatic variables in patients with SLE in the early period after starting high dose corticosteroid treatment may predict the subsequent development of ON. In addition, the presence of antiphospholipid antibody (aPL) has been proposed to predispose towards ON, but its role remains controversial.

Recently, some large scale studies failed to show any association between aPL and ON. We also measured aPL for 45 patients in this study and found no positive relation between ON and the presence of aPL positivity.

In 14 of the 32 patients with ON the first MRI already showed positive (fig 1, Nos 19–32). Although the assumption is that these patients already had ON before steroid treatment started, we believe that these patients should have shown normal MRI findings if they had been examined within two months after the start of corticosteroid treatment because the first MR images in 14 patients were obtained significantly later than those of the 18 remaining patients in the ON group (92.6 (22.0) days vs 39.6 (19.9) days, p<0.0001).

In this prospective MRI study, hip and knee ON lesions occurred in 44% of patients with SLE, a percentage which was within the range reported by most other studies (10–52%). All our patients with ON lesions were asymptomatic during the follow up period of 12 months, but in other reports some patients...
were symptomatic and needed surgical treatment. Segmental collapse is reported to be mainly a matter of time and depends on the size of the necrotic lesion.19 Although new osteonecrotic lesions appear after the follow up period only rarely, further follow up is recommended.

In conclusion, we found that in patients with SLE ON lesions developed very early (1–2 months) after starting high dose corticosteroid treatment. We think that MRI is useful not only in detecting early development of osteonecrotic lesions but also in examining the risk factors for their development.

Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment

K Oinuma, Y Harada, Y Nawata, K Takabayashi, I Abe, K Kamikawa and H Moriya

Ann Rheum Dis 2001 60: 1145-1148
doi: 10.1136/ard.60.12.1145

Updated information and services can be found at:
http://ard.bmj.com/content/60/12/1145

These include:

References
This article cites 19 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/60/12/1145#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Calcium and bone (725)
- Musculoskeletal syndromes (4951)
- Connective tissue disease (4253)
- Immunology (including allergy) (5144)
- Systemic lupus erythematosus (571)
- Clinical diagnostic tests (1282)
- Radiology (1113)
- Radiology (diagnostics) (750)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/